Stability of Cyanocobalamine in Sugar Coated Tablets
Stability of Cyanocobalamine in Sugar Coated Tablets
Stability of Cyanocobalamine in Sugar Coated Tablets
Health Science Laboratories, Consumer Healthcare Company, Takeda Pharmaceutical Company Limited, 17-85,
Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan
b Pharmaceutical Technology Research and Development Laboratories, Pharmaceutical Production Division,
Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan
Received 31 July 2006; received in revised form 24 November 2006; accepted 28 December 2006
Available online 9 January 2007
Abstract
The purpose of this study was to clarify the stability of cyanocobalamin (VB12 -CN) in sugar-coated tablets containing fursultiamine hydrochloride
(TTFD-HCl), riboflavin (VB2 ), and pyridoxine hydrochloride (VB6 ), and to identify the factors affecting the stability of VB12 -CN in these sugarcoated tablets. The stability of VB12 -CN was investigated using high-performance liquid chromatography while decomposition was evaluated
kinetically. The decomposition of VB12 -CN in sugar-coated tablets with high equilibrium relative humidity (more than 60%) under closed conditions
showed complex kinetics and followed an AvramiErofeev equation, which expresses a random nucleation (two-dimensional growth of nuclei)
model. We showed that equilibrium relative humidity, the incorporation of VB2 and VB6 , and sugar coating, are the main factors influencing
decomposition and that these factors cause the complex decomposition kinetics.
2007 Elsevier B.V. All rights reserved.
Keywords: Cyanocobalamin; Stability; Sugar-coated tablets; Equilibrium relative humidity; Riboflavin; Pyridoxine hydrochloride
1. Introduction
Vitamin B combinations are a well-recognized treatment of
nerve pain, muscle pain, tired eyes, stiff shoulders, and lumbar pain, and usually consist of a combination of thiamine
(VB1 ), riboflavin (VB2 ), pyridoxine hydrochloride (VB6 ),
and cyanocobalamin (VB12 -CN). Fursultiamine hydrochloride
(TTFD-HCl) is a well-known thiamine derivative with a better bioavailability than thiamine in humans, and is therefore
often used in preference to thiamine in such combinations.
Several dosage forms of such vitamin B combinations are available, such as bottled nutritive drinks, capsules, and tablets. It is
often necessary to take vitamin B combinations for long periods and, as patients usually prefer to take sugar-coated tablets,
these are often used to increase compliance. Sugar-coated tablets
have several advantages over other formulations: masking of the
unpleasant odor and taste of vitamins, elegant appearance, and
ease of swallowing.
When developing sugar-coated tablets containing a vitamin
B combination, it is necessary to consider the stability of the
Corresponding author. Tel.: +81 6 6300 6896; fax: +81 6 6300 6788.
E-mail address: Ohmori [email protected] (S. Ohmori).
0378-5173/$ see front matter 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.ijpharm.2006.12.044
162
used in solid dosage forms in the pharmaceutical field. In particular, there are few stability studies of VB12 -CN in sugar-coated
tablets using the HPLC method. In the present study, we investigated the stability and decomposition kinetics of VB12 -CN in
sugar-coated tablets containing TTFD-HCl, VB2 , and VB6 using
the HPLC method, and compared it with the stability of VB12 CN in powders, granules, and plain tablets. In order to clarify
the factors affecting the stability of VB12 -CN in sugar-coated
tablets, we evaluated the stability of VB12 -CN in sugar-coated
tablets under various conditions of equilibrium relative humidity
(ERH), in sugar-coated tablets lacking one of the other vitamins,
and in halved sugar-coated tablets.
2. Materials and methods
2.1. Materials
The following vitamins were used in the study: cyanocobalamin (VB12 -CN, Aventis Pharma S.A., France), fursultiamine
hydrochloride (TTFD-HCl, Takeda Pharmaceutical Company
Limited, Japan), riboflavin (VB2 , Takeda Pharmaceutical Company Limited, Japan), and pyridoxine hydrochloride (VB6 ,
Takeda Pharmaceutical Company Limited, Japan). Lactose
(Meggle GmbH, Germany) was used as a diluent. Corn starch
(Nihon Cornstarch Co., Japan) was used as both a diluent
and a disintegrant. Hydroxypropylcellulose (HPC-L, Nippon
Soda Co., Ltd., Japan) was used as a binder. Magnesium
stearate (Sakai Chemical Industrial Co., Ltd., Japan) was used
as a lubricant. Sucrose (Ensuiko Sugar Refining Co., Japan),
talc (Matsumura Sangyo Co., Japan), titanium dioxide (Ishihara Sangyo Kaisha Ltd., Japan), and powdered acacia (San-ei
Yakuhin Boueki Co., Japan) were used for sugar coating. The
above vitamins and excipients were in compliance with The
Japanese Pharmacopoeia Fourteenth Edition (2001). All other
chemicals were of reagent grade.
2.2. Manufacture of granules and plain tablets
TTFD-HCl, VB2 , VB6 , lactose, and corn starch were granulated with 0.12% VB12 -CN aqueous solution and 6% HPC-L
aqueous solution using a fluidized-bed granulator (FD-3S,
Powrex Co., Japan). Loaded weight in the fluidized-bed granulator was 1092 g, inlet air temperature 70 C, spray air pressure
0.1 MPa, and spray feed rate 810 g/min. After granulation,
the granules were milled using a screen mill (Power Mill,
Showa Kagaku Kikai Kosakusho Co., Ltd., Japan) with 1.5 mm
screen size. The milled granules were mixed manually with
corn starch and magnesium stearate in a plastic bag. Lubricated
granules were compressed using a rotary compression machine
(Correct 19 K, Kikusui Seisakusho Ltd., Japan) with 8-mm
diameter convex punches (radius 6.5 mm). Tablet weight was
170 mg, compression pressure 68 kN/punch, and rotation speed
20 rpm.
Each plain tablet contained 0.01 mg VB12 -CN, 54.58 mg
TTFD-HCl, 4.95 mg VB2 , 5.0 mg VB6 , 68.46 mg lactose,
31.5 mg corn starch, 5.0 mg HPC-L and 0.5 mg magnesium
stearate. When tablets lacking one of the vitamins were man-
(1)
163
(2)
Fig. 1. Stability of VB12 -CN in powders. (X) Decomposition rate. (a) Zero-order
plots; (b) Jander plots. () 40 C/6%RH; () 40 C/57%RH; () 40 C/75%RH.
164
Fig. 2. Stability of VB12 -CN in granules containing TTFD-HCl, VB2 , and VB6 .
(X) Decomposition rate. (a) Zero-order plots; (b) Jander plots. () 40 C/6%RH;
() 40 C/57%RH; () 40 C/75%RH.
(3)
Rate constant
R2
Powders at 40 C/75%RH
Zero-order
First-order
Jander
0.03
0.04
0.02
0.7968
0.8092
0.9553
Granules at 40 C/75%RH
Zero-order
First-order
Jander
0.07
0.03
0.05
0.7813
0.8243
0.9886
Granules at 40 C/57%RH
Zero-order
First-order
Jander
0.05
0.02
0.03
0.7194
0.7450
0.9780
Fig. 3. Stability of VB12 -CN in plain tablets containing TTFD-HCl, VB2 , and
VB6 at 40 C. (X) Decomposition rate. () ERH 44%; () ERH 65%.
165
166
Table 2
Values of m for solid-state decompositions (compiled from Hancock and Sharp, 1972; Umeda et al., 1985)
m
Equation
0.54
0.57
0.57
0.62
1.00
1.07
1.11
1.24
2.00
3.00
1 (1 X)1/3
Mechanism
= kt1/2
(Jander equation)
(1 X)ln(1 X) + X = kt
(1 2X/3) (1 X)2/3 = kt (GinstlingBrounshtein equation)
X2 = kt
ln(1/(1 X)) = kt
1 (1 X)1/3 = kt
1 (1 X)1/2 = kt
X = kt
ln(1/(1 X))1/2 = kt (AvramiErofeev equation)
ln(1/(1 X))1/3 = kt (AvramiErofeev equation)
R2
0.9996
40 C
0.04
0.9887
0.9238
0.9195
0.7779
0.8921
0.9606
0.9456
0.9368
0.7995
0.9144
0.9693
0.9915
Three-dimensional diffusion
Two-dimensional diffusion
Three-dimensional diffusion
One-dimensional diffusion
Random nucleation (one nucleus on each particle)
Phase boundary reaction (spherical symmetry)
Phase boundary reaction (cylindrical symmetry)
Zero-order mechanism
Random nucleation (two-dimensional growth of nuclei)
Random nucleation (three-dimensional growth of nuclei)
40 C
167
168
Hancock, J.D., Sharp, J.H., 1972. Method of comparing solid-state kinetic data
and its application to the decomposition of kaolinite, brucite, and BaCO3 . J.
Am. Ceram. Soc. 55, 7477.
Harada, K., Saito, I., Miura, H., Suzuki, K., Utsumi, I., 1969. Studies on vitamin
B12 . I. Thiamine as a degradation factor of cobalamins. Yakugaku Zasshi
89, 464468.
Heidemann, D.R., Jarosz, P.J., 1991. Preformulation studies involving moisture
uptake in solid dosage forms. Pharm. Res. 8, 292297.
Horioka, M., Aoyama, T., Takata, K., Maeda, T., Shirahama, K., 1974. Degradation of propantheline bromide and dried aluminum hydroxide gel in
powdered preparations. Yakuzaigaku 34, 1621.
Ichikawa, M., Ide, N., Shiraishi, S., Ono, K., 2005. Effect of various halide
salts on the incompatibility of cyanocobalamin and ascorbic acid in aqueous
solution. Chem. Pharm. Bull. 53, 688690.
Jacob, J.T., Nessel, R.J., Blodinger, J., 1968. Stability of cyanocobalamin in
film-coated multivitamin tablets. J. Pharm. Sci. 57, 18541857.
Ohmori, S., Ohno, Y., Makino, T., Kashihara, T., 2004a. Improvement of impact
toughness of sugar-coated tablets manufactured by the dusting method.
Chem. Pharm. Bull. 52, 322328.
Ohmori, S., Ohno, Y., Makino, T., Kashihara, T., 2004b. Effect of moisture
on impact toughness of sugar-coated tablets manufactured by the dusting
method. Chem. Pharm. Bull. 52, 329334.
Ohmori, S., Ohno, Y., Makino, T., Kashihara, T., 2004c. Development and evaluation of the tablets coated with the novel formulation termed thin-layer
sugarless coated tablets. Int. J. Pharm. 278, 459469.
Ohmori, S., Ohno, Y., Makino, T., Kashihara, T., 2005. Application of an electronic nose system for evaluation of unpleasant odor in coated tablets. Eur.
J. Pharm. Biopharm. 59, 289297.
Okazaki, K., Nishigaki, R., Hanano, M., 1989. Equation and accelerating factor
of degradation in cocarboxylase free ester lyophilizate. Yakuzaigaku 49,
141147.
Okazaki, K., Nishigaki, R., Hanano, M., 1990. Relationship between degradation rate and relative humidity, temperature, or physical pretreatments of
carboxylase free ester lyophilizate. Yakuzaigaku 50, 141148.
Okusa, N., 1975. Prediction of stability of drugs. III. Application of Weibull
probability paper to prediction of stability. Chem. Pharm. Bull. 23, 794
802.
Seki, H., Hayashi, T., Okusa, N., 1980. An application of weighted least-squares
analysis to Weibull probability paper for prediction of stability of drug
products. Yakuzaigaku 40, 201207.
Terao, M., Marui, E., Tanaka, K., Nakao, Y., 1980. Studies on the formulation and admixture of parental preparations. I. Degradation of ascorbic acid
and cyanocobalamin by sodium bisulfite added to ascorbic acid injection.
Yakugaku Zasshi 100, 8187.
The Japanese Pharmacopoeia Fourteenth Edition, 2001. Hirokawa Publishing
Co., Japan.
Toyama Pharmaceutical Research Association, 1992. Studies on the Stability
of Vitamin B Complex-Combined-Preparations, Stability of Vitamin B1 ,
B6 , B12 preparations, following proprietary standard. Kateiyakukenkyu (in
Japanese) 11, 3340.
Umeda, T., Ohnishi, N., Yokoyama, T., Kuroda, T., Kita, Y., Kuroda, K., Tatsumi, E., Matsuda, Y., 1985. A kinetic study on the isothermal transition of
polymorphic forms of tolbutamide and mefenamic acid in the solid state at
high temperatures. Chem. Pharm. Bull. 33, 20732078.
Yoshioka, S., 1995. Stability of Drugs and Dosage Forms. Nankodo Co. Ltd,
Japan (in Japanese).